Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab
| Autor: | Jacqueline K. Suen, Michael A. Warso, John L. Villano, Stacy S. Shord, Linda R. Bressler |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Skin Neoplasms Palliative care Cetuximab Gene Expression Antineoplastic Agents Antibodies Monoclonal Humanized Recurrence Internal medicine medicine Carcinoma Humans Pharmacology (medical) Aged 80 and over Pharmacology integumentary system biology business.industry Palliative Care Antibodies Monoclonal Cancer Squamous cell skin cancer Prognosis medicine.disease ErbB Receptors Monoclonal Carcinoma Squamous Cell biology.protein Skin cancer Antibody business medicine.drug |
| Zdroj: | Anti-Cancer Drugs. 18:827-829 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/cad.0b013e32809ef9e0 |
| Popis: | Cetuximab (Erbitux) is a recombinant, chimeric monoclonal antibody that binds with high affinity to the extracellular ligand-binding domain of human epidermal growth factor receptor. We report a case of repeated responses to cetuximab in a patient with nonresectable squamous cell skin cancer having strong human epidermal growth factor receptor expression. Nonmelanoma skin cancer is the most common cancer in the US, with more than 1 million new cases detected annually, of which 20-25% are squamous cell carcinomas. Although most primary cutaneous squamous cell carcinomas have a high clinical cure rate and are easily treated, the small subset of cancers that recur or metastasize has a poor prognosis, and accounts for approximately 2000 deaths per year. Treatment with cetuximab should be considered for human epidermal growth factor receptor expressing tumors in a palliative setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|